Hot Warren Buffett Stocks To Invest In Right Now

Hot Warren Buffett Stocks To Invest In Right Now: Aethlon Med ical Inc (AEMD)

Aethlon Medical, Inc. (Aethlon), incorporated on April 17, 1991, is a developmental-stage company. The Company is focused on creating medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions.

The Company's Aethlon ADAPT (Adaptive Dialysis-Like Affinity Platform Technology) system is a revenue-stage technology platform that provides the basis for a new class of devices that provide rapid, selective removal of disease promoting particles from the entire circulatory system. The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under the Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers.

The Aethlon Hemopurifier

The Company's Hemopurifier is a medical device that targets the rapid elimination of life-threatening infectious disease and cancer glycopathogens from circulation. Under the feasibility study protocol, the Company will enroll ten end-stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. In addition to augmenting the early viral kinetic response to SOC, the Company's Hemopurifier provides a candidate solution for viral rebound patients who traditionally are forced to discontinue therapy at the point HCV establishes resistance to drug regimens. Additionally, the Company's Hemopurifier represents a therapeutic strategy to address the population of HCV-infected dialysis patients for which SOC and all-antiviral strategies may be contraindicated or not cleared.

In design, the Company's Hemopurifier consists of the affinity lectin Galanthus nivalis agglutinin (GNA) immobi! lized in the outer-capillary space of advanced plasma membrane technology. The design allows for extracorporeal therapeutic deli very to occur on standard CRRT and dialysis instruments alre! ady located in hospitals and clinics worldwide. The mechanism of the Hemopurifier to rapidly eliminate a broad-spectrum disease targets is based on GNA's ability to selectively bind high mannose signatures that are abundant on the surface of cancer-secreted exosomes and glycoproteins that reside on the outer membrane of infectious viral pathogens. The Company has also established a compassionate-use treatment program at the Medanta Medicity Institute in India that provides treatment access to HCV-infected individuals.

The Company's Hemopurifier has also been discovered to capture tumor-secreted exosomes underlying several forms of cancer. Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. In addition to treating HCV-infec ted individuals, the Company has conducted a single proof of principal treatment study related to the treatment of HIV. In the study, Hemopurifier therapy reduced viral load by 93% in an HIV-AIDS infected individual without the administration of antiviral drug therapy. The study protocol provided for 12 Hemopurifier treatments, each four hours in duration, that were administered over the course of one month. Researchers at a university have since discovered that the Hemopurifier is able to capture exosomes that transport NEF protein, which is known to suppress the immune response in HIV-infected individuals.

The Company has been assigned all rights and title to and interests in an invention and related worldwide patent rights for a method to treat cancer under an assignment agreement with the London Health Science Center Researc! h, Inc. (! LHSCRI) The agreement provides that the Company is responsible for paying certain patent application and filing costs as well as a 2% royalty on any future net sales. The Company has als! o exercis! ed an option to license a pending patent entitled, Method to Inhibit Proliferation and Growth of Metastases from The Trustees of Boston University. The license provides a development strategy for new cancer therapies by uniting drug agents that inhibit the spread of cancer-related metastases with filtration techniques already in the Aethlon Hemopurifier(R). The resulting devices would inhibit tumor growth by reducing the presence of circulating growth factors without interfering with surgical wound healing or the recovery of tissue injured by radiation therapy.

The Company competes with Asahi Kasei Kurary Medical.

Advisors' Opinion:

• [By James E. Brumley]

  Stocks as a whole haven't gotten the new year off on the best foot, but that's not to say every equity out there is in trouble. Indeed, some small cap stocks may actually be doing well - and poised to do well for a while - specifically because larger companies are seeing their stocks struggle. To that end, traders looking for a bullish bright spot to start the new year may want to take a closer look at Amedica Corporation (NASDAQ:AMDA), Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), and Aethlon Medical, Inc. (OTCMKTS:AEMD).

source from Top Stocks For 2015:http://www.topstocksblog.com/hot-warren-buffett-stocks-to-invest-in-right-now-3.html